We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bad blood

8 January 2018 By Liam Proud

The Danish pharma group offered to buy Belgium’s Ablynx, which is developing a bleeding-disorder treatment. The returns look healthy for Novo Nordisk, which will also get a cheap option on two other potential drugs. That suggests rival bidders may not be far behind.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)